Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients

Navina K Birk; Saniya Jain; Louis Massoud; Diya Ramesh; Lea Monday; Bruce Muma; Jonathan Williams; George Alangaden; Mayur Ramesh

doi:10.1093/ofid/ofac282

Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients

Open Forum Infect Dis. 2022 Jun 7;9(7):ofac282. doi: 10.1093/ofid/ofac282. eCollection 2022 Jul.

Authors

Navina K Birk¹, Saniya Jain¹, Louis Massoud¹, Diya Ramesh¹, Lea Monday¹, Bruce Muma¹, Jonathan Williams¹, George Alangaden¹, Mayur Ramesh¹

Affiliation

¹ Division of Infectious Diseases, Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan, USA.

Abstract

We completed a real-world analysis of 498 consecutive high-risk nonimmunocompromised and immunocompromised patients who received sotrovimab during the B.1.1.529 surge. Emergency department visits/hospitalizations and 30-day all-cause mortality between the 2 groups were similar. When administered early, sotrovimab is effective at preventing coronavirus disease 2019 progression in immunocompromised and nonimmunocompromised patients.

Keywords: COVID-19; immunocompromised hosts; monoclonal antibody; outcomes; sotrovimab.